Study of Olaparib and Durvalumab in IDH-Mutated Solid Tumors
- Status
- RECRUITING
- Phase
- PHASE2
Clinical Trials Related to Olaparib
Related studies linked through entity extraction aliases.
A Study of Pembrolizumab (MK-3475) With or Without Maintenance Olaparib in First-line Metastatic Squamous Non-small Cell Lung Cancer (NSCLC, MK-7339-008/KEYLYNK-008)
- Status
- COMPLETED
- Phase
- PHASE3
Study of Pembrolizumab With Maintenance Olaparib or Maintenance Pemetrexed in First-line (1L) Metastatic Nonsquamous Non-Small-Cell Lung Cancer (NSCLC) (MK-7339-006, KEYLYNK-006)
- Status
- COMPLETED
- Phase
- PHASE3
Hyperthermia and Olaparib in Treating Breast Cancer Patients With Chest Wall Recurrences
- Status
- TERMINATED
- Phase
- PHASE1
Using the Anticancer Drug Olaparib to Treat Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome With an Isocitrate Dehydrogenase (IDH) Mutation
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Olaparib in Treating Patients With Newly Diagnosed BRCA-Mutant Ovarian, Primary Peritoneal, or Fallopian Cancer Before Surgery
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- EARLY_PHASE1
Breast Cancer Treatment Based on Organ-like Culture
- Status
- UNKNOWN
- Phase
- N/A
Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant Ovarian, Primary Peritoneal, Fallopian Tube Cancers
- Status
- TERMINATED
- Phase
- PHASE1
A Phase II Clinical Trial Evaluating the Combination of Olaparib and Temozolomide for the Treatment of Advanced Uterine Leiomyosarcoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
- Status
- TERMINATED
- Phase
- PHASE1
Testing Olaparib and AZD6738 in IDH1 and IDH2 Mutant Tumors
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
177Lu-PSMA-617 Therapy and Olaparib in Patients With Metastatic Castration Resistant Prostate Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Study of DNA Damage, Angiogenesis, and PD-L1 Inhibitors in Advanced Solid Tumors
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Testing the Combination of the Anti-cancer Drugs Copanlisib, Olaparib, and MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumors With Selected Mutations
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-7339-010/KEYLYNK-010)
- Status
- COMPLETED
- Phase
- PHASE3
A Translational Study of Single Agent Olaparib in the Treatment of Advanced Oesophagogastric Cancer
- Status
- UNKNOWN
- Phase
- PHASE2
A Study of Olaparib and Durvalumab in Prostate Cancer
- Status
- TERMINATED
- Phase
- PHASE2
AMTEC IIT: Phase 2 Multiarm Study in TNBC
- Status
- TERMINATED
- Phase
- PHASE2
Targeting Resistant Prostate Cancer With ATR and PARP Inhibition (TRAP Trial)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutations
- Status
- RECRUITING
- Phase
- PHASE2